- Home
- ACIU vs INBK Comparison
ACIU vs INBK Comparison
Compare ACIU & INBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- INBK
- Stock Information
- Founded
- ACIU 2003
- INBK 1999
- Country
- ACIU Switzerland
- INBK United States
- Employees
- ACIU N/A
- INBK N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- INBK Major Banks
- Sector
- ACIU Health Care
- INBK Finance
- Exchange
- ACIU Nasdaq
- INBK Nasdaq
- Market Cap
- ACIU 270.1M
- INBK 289.7M
- IPO Year
- ACIU 2016
- INBK N/A
- Fundamental
- Price
- ACIU $2.65
- INBK $30.39
- Analyst Decision
- ACIU Strong Buy
- INBK Buy
- Analyst Count
- ACIU 2
- INBK 3
- Target Price
- ACIU $12.00
- INBK $41.00
- AVG Volume (30 Days)
- ACIU 203.0K
- INBK 33.3K
- Earning Date
- ACIU 03-13-2025
- INBK 01-22-2025
- Dividend Yield
- ACIU N/A
- INBK 0.79%
- EPS Growth
- ACIU N/A
- INBK 203.16
- EPS
- ACIU N/A
- INBK 2.88
- Revenue
- ACIU $48,505,404.00
- INBK $117,652,000.00
- Revenue This Year
- ACIU $86.78
- INBK N/A
- Revenue Next Year
- ACIU $118.22
- INBK $19.61
- P/E Ratio
- ACIU N/A
- INBK $10.55
- Revenue Growth
- ACIU 4097200.00
- INBK 39.44
- 52 Week Low
- ACIU $2.25
- INBK $24.18
- 52 Week High
- ACIU $4.98
- INBK $43.26
- Technical
- Relative Strength Index (RSI)
- ACIU 47.51
- INBK 31.34
- Support Level
- ACIU $2.39
- INBK $31.08
- Resistance Level
- ACIU $2.74
- INBK $33.72
- Average True Range (ATR)
- ACIU 0.14
- INBK 1.21
- MACD
- ACIU 0.01
- INBK -0.10
- Stochastic Oscillator
- ACIU 56.52
- INBK 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.